毒理基因組學(xué)是利用DNA微陣列技術(shù)，研究化合物作用于機(jī)體后的基因變化，將組學(xué)技術(shù)與傳統(tǒng)毒理學(xué)及組織病理學(xué)相結(jié)合，評(píng)價(jià)和預(yù)測(cè)化合物的毒性的一門(mén)學(xué)科。隨著毒理基因組學(xué)的廣泛應(yīng)用，免疫毒理學(xué)領(lǐng)域也開(kāi)始利用基因表達(dá)譜來(lái)分析化合物的免疫毒性。目前認(rèn)為免疫毒理基因組學(xué)可能在下述3個(gè)方面具有較高的應(yīng)用價(jià)值，即免疫毒性物質(zhì)的篩選、免疫毒性作用機(jī)制的研究以及免疫毒性風(fēng)險(xiǎn)評(píng)估?，F(xiàn)圍繞這3個(gè)方面，對(duì)毒理基因組學(xué)在免疫毒理學(xué)領(lǐng)域中的應(yīng)用進(jìn)行闡述。

Toxicogenomics is the subject that researches on the genetic changes by using DNA microarray technology after the compounds acting on the body. It combines omics technologies with conventional toxicology and histopathology in order to evaluate and predict the toxicity of a compound. With the wide application of toxicogenomics, it begins to analyze the immunotoxicity of compounds by using gene expression profiling in immunotoxicity. Currently, scientists believe that the immunotoxicogenomics may have higher value in the following three areas, immunotoxicity screening substances, immune mechanisms of toxicity, and immunotoxicity risk assessment. Therefore, it was discussed in these three aspects of application of immune toxicology in this paper.

國(guó)家“重大新藥創(chuàng)新”科技重大專(zhuān)項(xiàng)-藥物安全評(píng)價(jià)技術(shù)平臺(tái)（2012ZX09302001）